Person:
DÖLEK, RABİA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

DÖLEK

First Name

RABİA

Name

Filters

20231
Reset filters

Settings

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Prognostic value of estrogen receptors in patients who underwent prostatectomy for non-metastatic prostate cancer
    (Spandidos Publ Ltd, 2023-02-01) Aydın, Yavuz Mert; Şahin, Ahmet Bilgehan; Dölek, Rabia; Vuruşkan, Berna Aytaç; Ocakoğlu, Gökhan; Vuruşkan, Hakan; Yavaşçaoğlu, İsmet; Coşkun, Burhan; AYDIN, YAVUZ MERT; ŞAHİN, AHMET BİLGEHAN; DÖLEK, RABİA; AYTAÇ VURUŞKAN, BERNA; OCAKOĞLU, GÖKHAN; VURUŞKAN, HAKAN; YAVAŞCAOĞLU, İSMET; COŞKUN, BURHAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0002-6287-6767; 0000-0002-7846-0870; 0000-0002-1114-6051; 0000-0002-8242-9921; AAH-9704-2021; AFP-3055-2022; HSH-9815-2023; JCO-5169-2023; AAH-5180-2021; AAM-4927-2020; EEJ-1452-2022; EFH-9523-2022; EIN-0828-2022
    Estrogen receptors in prostate cancer (PCa) are a subject of debate. The aim of the present study was to investigate whether estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta) impact the biochemical recurrence (BCR) of non-metastatic PCa after surgery. Following the application of the exclusion criteria, data from 108 patients who underwent laparoscopic radical prostatectomy between January 2011 and December 2019 were retrospectively evaluated. A total of 36 patients with BCR constituted the BCR group. The control group was formed using the Propensity Score Matching (PSM) method with a 1:2 ratio, including parameters with well-studied effects on BCR. The median follow-up time was 74.3 (range, 30-127.5) months in the BCR group and 66.6 (range, 31.5-130) months in the control group. Pathology specimens from the two groups were immunohistochemically stained with ER alpha and ER beta antibodies. Logistic regression analysis and survival analysis were performed. No differences in clinicopathological characteristics were detected between the two groups. The patients with ER alpha(-)/ER beta(+) staining results had a significantly fewer BCRs than other patients (P=0.024). In the logistic regression analysis, patients with ER alpha(-)/ER beta(+) PCa also had a significantly lower risk of recurrence (P=0.048). In the survival analysis, the 5-year BCR-free survival rate of patients with ER alpha(-)/ER beta(+) PCa was higher than that of other patients (85.7 vs. 66.1%; P=0.031). Excluding the effects of well-studied risk factors for recurrence by the PSM method, the present study showed that ER alpha and ER beta have prognostic value for non-metastatic PCa. The 5-year BCR-free survival rate is significantly higher in patients whose PCa tissue has ER alpha(-)/ER beta(+) staining results.